Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Hematologic Malignancies
Filter by Topic
Leukemia
Daratumumab Improves Overall Survival in Multiple Myeloma
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
February 2016, Vol 7, No 1
With the accelerated FDA approval in December 2015 of the anti-CD38 monoclonal antibody daratumumab (Darzalex) for patients with multiple myeloma who received ≥3 previous therapies, studies of the drug presented at ASH 2015 were of great interest.
Read Article
Consistent Benefit Over Time in Elotuzumab Studies
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
February 2016, Vol 7, No 1
The immunostimulatory monoclonal antibody elotuzumab (Empliciti), which was approved by the FDA in December 2015, is being studied in combination with immunomodulatory drugs and proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Results presented at ASH 2015 show continued benefit from these regimens.
Read Article
All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
February 2016, Vol 7, No 1
With the recent FDA approval of the first oral proteasome inhibitor ixazomib (Ninlaro), patients with relapsed or refractory multiple myeloma who have received previous treatment now have access to an all-oral regimen. The FDA-indicated triplet regimen of ixazomib, lenalidomide (Revlimid), and dexamethasone (Decadron) significantly improved progression-free survival (PFS) compared with the doublet of lenalidomide and dexamethasone, reported Philippe Moreau, MD, University of Nantes, France, at ASH 2015.
Read Article
Multiple Myeloma Therapy in 2015: “An Extraordinary Moment in Oncology”
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
February 2016, Vol 7, No 1
The year 2015 saw an explosion of new drugs approved by the FDA and new indications for drugs already on the market for multiple myeloma. Overall, 4 new drugs from 2 new classes were approved in 2015, changing the standard of care for patients with this disease.
Read Article
Myeloablative Conditioning Remains Standard of Care in Patients with Myelodysplastic Sydrome
By
Phoebe Starr
Hematologic Malignancies
,
Myelodysplastic Syndromes
March 2016, Vol 7, No 2
Traditional myeloablative conditioning remains the standard of care for preparing patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) for transplant, according to a randomized trial from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The study, presented as a late-breaker at ASH 2015, was halted after a reduced-intensity conditioning (RIC) regimen proved less effective.
Read Article
Rituximab Boosts Chemotherapy Benefit in Patients with B-Cell Precursor ALL
By
Dana Taylor
Hematologic Malignancies
,
Leukemia
March 2016, Vol 7, No 2
In patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the addition of rituximab (Rituxan) to chemotherapy significantly improved event-free survival in a large European study.
Read Article
Pembrolizumab Shows Promise in Multiple Myeloma
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
March 2016, Vol 7, No 2
Monoclonal antibodies targeting PD-1 may be effective in multiple myeloma, according to early data from 2 clinical trials on pembrolizumab (Keytruda) presented at ASH 2015.
Read Article
First-in-Human CAR T-Cell Trial Demonstrates Activity in Multiple Myeloma
By
Dana Taylor
Emerging Therapies
,
Hematologic Malignancies
,
Multiple Myeloma
,
Personalized Medicine
March 2016, Vol 7, No 2
Chimeric antigen receptor (CAR) T-cell therapy has been striking in various hematologic malignancies, and for the first time this treatment approach is being evaluated in multiple myeloma.
Read Article
A 3-Drug Regimen the Preferred Approach in Newly Diagnosed Multiple Myeloma
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
March 2016, Vol 7, No 2
Although the cost of treating newly diagnosed patients with multiple myeloma is greatly increased with the use of 3 drugs, 2-drug regimens should no longer be considered adequate, according to new data presented at ASH 2015.
Read Article
Value-Based Strategies for Patients with Multiple Myeloma
Hematologic Malignancies
,
Multiple Myeloma
,
Value-Based Care
December 2015, Vol 6, No 11
At the Fifth Annual Conference of the Association for Value-Based Cancer Care in Washington, DC, Grant Lawless, RPh, MD, FACP, of the University of Southern California, Los Angeles, moderated a multidisciplinary panel on value-based care for patients with multiple myeloma.
Read Article
Page 10 of 11
2
3
4
5
6
7
8
9
10
11
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma